Calliditas Presents Data from the NefIgArd Phase 3 trial at the 17th International Symposium on IgA Nephropathy (IIgANN) Tokyo 2023 September 29, 2023 14:00 CET Non Regulatory Read more
STADA and Calliditas announce the filing for full marketing authorization of Kinpeygo® in the EU September 28, 2023 12:01 CET Non Regulatory Read more
Calliditas Therapeutics granted orphan drug designation by the FDA for the treatment of Alport syndrome with setanaxib September 27, 2023 19:06 CET Non Regulatory Read more
Calliditas Therapeutics to Present Nefecon Data at the 17[th] International Symposium on IgA Nephropathy (IIgANN) September 25-27 in Tokyo September 19, 2023 16:00 CET Non Regulatory Read more
Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet August 15, 2023 08:00 CET Non Regulatory Read more
Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib July 13, 2023 08:00 CET Non Regulatory Read more
Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO[®] June 21, 2023 09:00 CET Non Regulatory Read more
Calliditas Announces Late-Breaking Presentations at the 60th European Renal Association (ERA) Congress 2023 May 5, 2023 14:30 CET Non Regulatory Read more
Calliditas to participate in upcoming investor conferences March 31, 2023 17:00 CET Non Regulatory Read more
Calliditas Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA nephropathy February 2, 2023 09:15 CET Non Regulatory Read more
China CDE/NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy December 30, 2022 08:30 CET Non Regulatory Read more
Calliditas CEO acquires shares through the exercise of Calliditas’ warrant program 2019/2022 December 20, 2022 21:15 CET Non Regulatory Read more
Calliditas to host fireside chat with its China commercial partner, Everest Medicines December 9, 2022 08:00 CET Non Regulatory Read more
Calliditas’ partner Everest Medicine’s New Drug Application for Nefecon is accepted by the China NMPA November 15, 2022 08:00 CET Non Regulatory Read more
Key Opinion Leader Fireside Chat with Professor Richard Lafayette on the US IgAN Treatment Landscape November 7, 2022 09:00 CET Non Regulatory Read more
Kidney International Publishes Results from NefIgArd Phase 3 Trial Evaluating TARPEYO[®] (budesonide) in IgA Nephropathy October 19, 2022 15:30 CET Non Regulatory Read more
Calliditas’ partner STADA launches the first medicine authorized in the EU for treating primary IgA nephropathy September 20, 2022 14:00 CET Non Regulatory Read more
Calliditas announces additions to the management team July 11, 2022 12:30 CET Non Regulatory Read more
Calliditas Therapeutics establishes a U.S. At-the-Market Program June 28, 2022 23:15 CET Non Regulatory Read more
First patient randomized in Phase 2 trial in head and neck cancer May 17, 2022 11:00 CET Non Regulatory Read more
Calliditas Therapeutics to participate in upcoming investor conferences May 10, 2022 08:30 CET Non Regulatory Read more
Calliditas CEO acquires shares through the exercise of Calliditas’ warrant program 2018/2022 March 24, 2022 12:00 CET Non Regulatory Read more
Calliditas provides a regulatory update on EMA process for Nefecon March 22, 2022 08:00 CET Non Regulatory Read more
Expansion of Everest Medicine’s licence agreement to include South Korea March 14, 2022 07:00 CET Non Regulatory Read more
First patient randomized in pivotal TRANSFORM study with setanaxib February 15, 2022 10:30 CET Non Regulatory Read more
Calliditas Therapeutics Announces Commercial Availability and Initial Sales of TARPEYO™ January 28, 2022 08:00 CET Non Regulatory Read more
FDA grants Calliditas Therapeutics Accelerated Approval of TARPEYO™ (budesonide) to Reduce Proteinuria in IgA Nephropathy December 15, 2021 21:45 CET Non Regulatory Read more
Calliditas announces poster presentations at ASN Digital Kidney Week 2021 November 3, 2021 08:00 CET Non Regulatory Read more
Calliditas announces acquisition of remaining Genkyotex minority shares October 7, 2021 08:00 CET Non Regulatory Read more
Calliditas Receives FDA Fast Track Designation for setanaxib in PBC August 9, 2021 08:00 CET Non Regulatory Read more
Calliditas Therapeutics to Present at Jefferies Virtual Healthcare Conference May 28, 2021 12:00 CET Non Regulatory Read more
Calliditas Therapeutics to host conference call to provide Business Update for the first quarter of 2021 May 14, 2021 14:00 CET Non Regulatory Read more
Calliditas promotes Andrew Udell to President, North America May 3, 2021 14:30 CET Non Regulatory Read more
Calliditas strengthens its US Commercial and Medical Affairs Organization March 8, 2021 08:30 CET Non Regulatory Read more
Calliditas Therapeutics to Host Key Opinion Leader Perspectives Webinar on the Pathophysiology and Treatment of IgA Nephropathy in Clinical Practice March 4, 2021 14:30 CET Non Regulatory Read more
First Patient Dosed in NefIgArd Open Label Extension Study February 4, 2021 08:30 CET Non Regulatory Read more
Calliditas Announces Full Enrollment of the Phase 3 NefIgArd Trial January 21, 2021 08:30 CET Non Regulatory Read more
Positive Phase 1 results in high-dose setanaxib trial January 18, 2021 08:00 CET Non Regulatory Read more
Agenda for Calliditas virtual R&D Day on January 20, 2021 January 15, 2021 09:00 CET Non Regulatory Read more
Calliditas announces final outcome of simplified mandatory offer to the shareholders of Genkyotex December 16, 2020 17:47 CET Non Regulatory Read more
Save the date: Calliditas to host a Capital Markets Day in Stockholm, Sweden, on January 20, 2021 December 9, 2020 13:00 CET Non Regulatory Read more
Calliditas Therapeutics to host conference call to provide Business Update and 2020 Q3 report November 11, 2020 11:00 CET Non Regulatory Read more
Calliditas Therapeutics to host conference call on positive topline results from pivotal phase 3 NefIgArd trial November 9, 2020 10:00 CET Non Regulatory Read more
Calliditas Announces Poster and Presentation at ASN Digital Kidney Week 2020 October 19, 2020 08:00 CET Non Regulatory Read more
The 200[th] patient’s last visit completed in Part A of NefIgArd supporting topline readout in pivotal Phase 3 trial in Q4, 2020 October 1, 2020 09:45 CET Non Regulatory Read more
First patient in China enrolled in clinical phase 3 study NefIgArd with lead candidate Nefecon September 8, 2020 08:00 CET Non Regulatory Read more
Calliditas Therapeutics to host conference call to provide Business Update and 2020 Q2 report August 11, 2020 14:00 CET Non Regulatory Read more
CEO Renée Aguiar-Lucander exercises warrants and invests SEK 15.7m (appr. USD 1.7m) in Calliditas June 22, 2020 08:00 CET Non Regulatory Read more
Calliditas provides a corporate business update in the context of the Covid-19 pandemic April 27, 2020 08:00 CET Non Regulatory Read more
Calliditas strengthens its US Commercial Organization April 1, 2020 08:00 CET Non Regulatory Read more
Positive opinion received from EMA Paediatric Committee on the Paediatric Investigation Plan for Nefecon for the treatment of IgAN January 22, 2020 08:00 CET Non Regulatory Read more
The pivotal Phase 3 clinical trial NefIgArd Part A fully recruited December 23, 2019 08:00 CET Non Regulatory Read more
Calliditas Therapeutics Capital Markets Day today November 4 November 4, 2019 08:00 CET Non Regulatory Read more
Save the date: Calliditas to host Capital Markets Day in Stockholm on November 4, 2019 October 1, 2019 13:00 CET Non Regulatory Read more
Calliditas Therapeutics to host conference call to provide Business Update and 2019 Q2 report August 12, 2019 12:00 CET Non Regulatory Read more
Calliditas Therapeutics to Present at Redeye Growth Day June 4, 2019 13:00 CET Non Regulatory Read more
Calliditas Therapeutics to host conference call to provide Business Update and 2019 Q1 report May 6, 2019 15:00 CET Non Regulatory Read more
Elmar Schnee and Diane Parks proposed as new board members of Calliditas Therapeutics April 5, 2019 11:15 CET Non Regulatory Read more
Calliditas Therapeutics to Present at the Needham Healthcare Conference April 3, 2019 13:00 CET Non Regulatory Read more
Calliditas Therapeutics to Present at March Investor Conferences March 4, 2019 10:00 CET Non Regulatory Read more
Calliditas Therapeutics to host conference call to provide Business Update and 2018 full-year report February 1, 2019 10:00 CET Non Regulatory Read more
Calliditas Therapeutics appoints Frank Bringstrup as VP Regulatory Affairs January 14, 2019 14:30 CET Non Regulatory Read more
Calliditas Therapeutics appoints Andrew Udell to VP Commercial, North America January 8, 2019 07:00 CET Non Regulatory Read more
Calliditas Therapeutics to present and attend investor conferences in November 2018 November 9, 2018 14:00 CET Non Regulatory Read more
Calliditas Therapeutics to host conference call to provide Q3 2018 Business Update October 30, 2018 08:00 CET Non Regulatory Read more
Presentation at International IgA Nephropathy Network meeting highlighting supportive post-hoc analysis of the NEFIGAN study October 1, 2018 08:00 CET Non Regulatory Read more
Post-hoc results from NEFIGAN study to be presented at the International IgA Nephropathy Network meeting (IIgANN) September 25, 2018 08:00 CET Non Regulatory Read more
Calliditas Therapeutics to host conference call to provide Q2 2018 Business Update August 13, 2018 08:00 CET Non Regulatory Read more
The 15th International Symposium on IgA nephropathy accepts Calliditas Therapeutics abstracts August 6, 2018 08:00 CET Non Regulatory Read more
Calliditas Therapeutics selected to present at the 25th Annual NewsMakers in the Biotech Industry August 1, 2018 08:00 CET Non Regulatory Read more
Trading in Calliditas’ share commences today on Nasdaq Stockholm June 29, 2018 08:00 CET Non Regulatory Read more
Pharmalink enters manufacturing agreement for Nefecon® October 31, 2012 15:23 CET Non Regulatory Read more
